Logo Logo
Hilfe
Hilfe
Switch Language to English

Walser, Matthias; Hermann, Matthias; Hufnagel, Markus; Haas, Nikolaus A.; Fischer, Marcus; Dalla-Pozza, Robert und Jakob, Andre (2020): Anakinra And Etanercept Combination Treatment in a Child With Severe, Nonresponsive Kawasaki Disease. In: Pediatric Infectious Disease Journal, Bd. 39, Nr. 10, E310-E313

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Kawasaki disease (KD) patients' resistance to treatment with intravenous immunoglobulins (IVIG) places them at high risk for an unfavorable progression of the disease. In these patients, there has been little evidence that alternative treatments are effective. Nevertheless, biologicals such as an interleukin-1-receptor blocker and tumor-necrosis-factor-alpha inhibitors increasingly have been used. If the patient does not respond to one of these therapeutics, a combination of 2 biologicals might be an alternative, but this is not yet generally accepted due to the potentially increased risk of infection. Here we report on a 3-month-old boy suffering from severe refractory KD. KD diagnosis was delayed due to the misinterpretation of a urinary tract infection and to the short and nonsimultaneous presence of classical KD symptoms. After complete KD later was able to be diagnosed, treatment with intravenous immunoglobulins was administered. However, the disease proved resistant to 2 courses of IVIG, as well as to corticosteroids. The patient developed giant coronary artery aneurysms early during the course of disease. Anakinra was initiated, but even with stepwise higher anakinra dosages, he remained febrile and coronary artery dimensions increased. Therefore, etanercept was added as a second biological. Only under combination treatment with anakinra and etanercept were his inflammation and fever able to be completely resolved. Coronary artery dimensions improved over time.

Dokument bearbeiten Dokument bearbeiten